Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 4/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.35 |
| ▸ | CDK2 | P24941 | 4/20 | 0.35 |
| ▸ | CDK4 | P11802 | 2/20 | 0.33 |
| ▸ | CCND1 | P24385 | 2/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2669083 | 0.78 | HRH1 (0.37) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL2669095 | 0.78 | CA2 (0.38) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL12574466 | 0.75 | HTR7 (0.46) | — | |
| SCHEMBL21133103 | 0.75 | — | — | |
| SCHEMBL2669089 | 0.73 | CCNE2 (0.45) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL2669118 | 0.72 | ALDH1A1 (0.41) | CCNE2CCNE1CDK2 | |
| SCHEMBL2669086 | 0.70 | ALOX15 (0.41) | — | |
| SCHEMBL2669124 | 0.69 | ALOX15 (0.43) | — | |
| SCHEMBL12574469 | 0.69 | GSK3B (0.37) | — | |
| SCHEMBL22724071 | 0.68 | SLC6A3 (0.37) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| WO-2009133687-A1 | CYCLOPENTYLACRYLIC ACID AMIDE DERIVATIVE | 杏林製薬株式会社 (JP) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | CCNE2 2492/4885CCNE1 2205/4885CDK2 3580/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | CCNE2 2492/4885CCNE1 2205/4885CDK2 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.